thiazoles has been researched along with Chylopericardium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Alimena, G; Breccia, M | 1 |
| Herndlhofer, S; Krauth, MT; Mitterbauer-Hohendanner, G; Schlögl, E; Schmook, MT; Valent, P | 1 |
| Aydin, Y; Eskazan, AE; Ferhanoglu, B; Gulturk, E; Ongoren, S; Soysal, T | 1 |
| Breccia, M; Isidori, A; Montefusco, E; Morra, E; Santini, V; Visani, G | 1 |
2 review(s) available for thiazoles and Chylopericardium
| Article | Year |
|---|---|
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
3 other study(ies) available for thiazoles and Chylopericardium
| Article | Year |
|---|---|
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2011 |
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Topics: Aged; Dasatinib; Diuretics; Drug Administration Schedule; Female; Furosemide; Glucocorticoids; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Severity of Illness Index; Thiazoles; Turkey | 2011 |
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Topics: Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |